Amycretin

Amycretin is a single molecule serving as a GLP-1 receptor agonist and an amylin receptor agonist. It is made by the Danish pharmaceutical company Novo Nordisk as a weight loss drug to be taken by mouth. 



  A form that can be injected via human skin is also under study.

Mechanism of action

The drug has a dual mechanism of action affecting appetite regulation and metabolism, which makes it different from other drugs being made for weight loss. 

Research

The company announced the results from the Phase I trial of amycretin's pill form. The company further announced the results of its 1B/2A trial in January 2025. The trial investigated the drug's safety, tolerability, and pharmacokinetics by injecting it into 125 patients via their skin. The treatment lasted up to 36 weeks.

References

Category:Chemicals